JP2018522567A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018522567A5 JP2018522567A5 JP2018506286A JP2018506286A JP2018522567A5 JP 2018522567 A5 JP2018522567 A5 JP 2018522567A5 JP 2018506286 A JP2018506286 A JP 2018506286A JP 2018506286 A JP2018506286 A JP 2018506286A JP 2018522567 A5 JP2018522567 A5 JP 2018522567A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- cell
- specific
- cells
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022069615A JP7566817B2 (ja) | 2015-08-07 | 2022-04-20 | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
| JP2024172910A JP2025000906A (ja) | 2015-08-07 | 2024-10-02 | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562202698P | 2015-08-07 | 2015-08-07 | |
| US62/202,698 | 2015-08-07 | ||
| PCT/US2016/045360 WO2017027291A1 (en) | 2015-08-07 | 2016-08-03 | Bispecific car t-cells for solid tumor targeting |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022069615A Division JP7566817B2 (ja) | 2015-08-07 | 2022-04-20 | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018522567A JP2018522567A (ja) | 2018-08-16 |
| JP2018522567A5 true JP2018522567A5 (enExample) | 2019-09-12 |
| JP7162530B2 JP7162530B2 (ja) | 2022-10-28 |
Family
ID=57984403
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018506286A Active JP7162530B2 (ja) | 2015-08-07 | 2016-08-03 | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
| JP2022069615A Active JP7566817B2 (ja) | 2015-08-07 | 2022-04-20 | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
| JP2024172910A Pending JP2025000906A (ja) | 2015-08-07 | 2024-10-02 | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022069615A Active JP7566817B2 (ja) | 2015-08-07 | 2022-04-20 | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
| JP2024172910A Pending JP2025000906A (ja) | 2015-08-07 | 2024-10-02 | 固形腫瘍を標的とする二重特異性ｃａｒ ｔ細胞 |
Country Status (9)
| Country | Link |
|---|---|
| US (3) | US11458167B2 (enExample) |
| EP (1) | EP3331920A4 (enExample) |
| JP (3) | JP7162530B2 (enExample) |
| CN (1) | CN108174604B (enExample) |
| AU (2) | AU2016306209B2 (enExample) |
| CA (1) | CA2994829A1 (enExample) |
| HK (1) | HK1256087A1 (enExample) |
| MX (1) | MX2018001568A (enExample) |
| WO (1) | WO2017027291A1 (enExample) |
Families Citing this family (88)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11201608393TA (en) | 2014-04-10 | 2016-11-29 | Seattle Children S Hospital Dba Seattle Children S Res Inst | Transgene genetic tags and methods of use |
| US11400115B2 (en) | 2014-04-23 | 2022-08-02 | Juno Therapeutics, Inc. | Methods for isolating, culturing, and genetically engineering immune cell populations for adoptive therapy |
| US11253546B2 (en) | 2014-12-15 | 2022-02-22 | The Regents Of The University Of California | Bispecific OR-gate chimeric antigen receptor responsive to CD19 and CD20 |
| US11458167B2 (en) * | 2015-08-07 | 2022-10-04 | Seattle Children's Hospital | Bispecific CAR T-cells for solid tumor targeting |
| AU2017213661B2 (en) | 2016-02-05 | 2022-06-02 | City Of Hope | Administration of engineered T cells for treatment of cancers in the central nervous system |
| CA3016287A1 (en) * | 2016-03-04 | 2017-09-08 | Novartis Ag | Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore |
| AU2017305170A1 (en) | 2016-08-02 | 2019-02-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Monoclonal antibodies targeting glypican-2 (GPC2) and use thereof |
| CN110291200B (zh) | 2016-12-12 | 2024-05-14 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体 |
| CA3068634A1 (en) * | 2017-06-30 | 2019-01-03 | Memorial Sloan Kettering Cancer Center | Compositions and methods for adoptive cell therapy for cancer |
| US12241097B2 (en) | 2017-06-30 | 2025-03-04 | Memorial Sloan Kettering Cancer Center | Compositions and methods for adoptive cell therapy for cancer |
| CA3068641A1 (en) * | 2017-06-30 | 2019-01-03 | Memorial Sloan Kettering Cancer Center | Compositions and methods for adoptive cell therapy |
| EP3661964A1 (en) * | 2017-07-31 | 2020-06-10 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-cd19/cd20 immunotherapy |
| CN109423495A (zh) * | 2017-08-24 | 2019-03-05 | 上海恒润达生生物科技有限公司 | 一种双靶向嵌合抗原受体及其用途 |
| AU2018352984B2 (en) | 2017-10-18 | 2024-02-01 | Precigen, Inc. | Polypeptide compositions comprising spacers |
| WO2019089855A1 (en) * | 2017-11-01 | 2019-05-09 | Juno Therapeutics, Inc. | Process for generating therapeutic compositions of engineered cells |
| BR112020008638A2 (pt) * | 2017-11-01 | 2020-10-20 | Juno Therapeutics Inc | receptores de antígenos quiméricos específicos para antígenos de maturação de células b (bcma) |
| AU2018359907A1 (en) | 2017-11-06 | 2020-05-07 | Fred Hutchinson Cancer Center | Combination of a cell therapy and a gamma secretase inhibitor |
| KR20250143360A (ko) | 2017-11-10 | 2025-10-01 | 더 유나이티드 스테이츠 오브 어메리카, 애즈 리프리젠티드 바이 더 세크러테리, 디파트먼트 오브 헬쓰 앤드 휴먼 서비씨즈 | 종양 항원을 타겟으로 하는 키메릭 항원 수용체 |
| WO2019111250A1 (en) * | 2017-12-05 | 2019-06-13 | The Medical Research Infrastructure And Health Services Fund Of The Tel Aviv Medical Center | T-cells comprising two different chimeric antigen receptors and uses thereof |
| ES2949855T3 (es) | 2017-12-05 | 2023-10-03 | Medical Res Infrastructure & Health Services Fund Tel Aviv Medical Ct | Linfocitos T que comprenden receptores antigénicos quiméricos anti-CD38 y ant-CD138 y los usos de los mismos |
| CN109970866B (zh) * | 2017-12-28 | 2022-10-04 | 上海细胞治疗研究院 | 一种cd28双向激活共刺激分子受体及其用途 |
| CN109970867B (zh) * | 2017-12-28 | 2022-10-18 | 上海细胞治疗研究院 | 一种cd40双向激活共刺激分子受体及其用途 |
| CN109970864A (zh) * | 2017-12-28 | 2019-07-05 | 上海细胞治疗研究院 | 一种双向激活共刺激分子受体及其用途 |
| US12491153B2 (en) | 2018-01-03 | 2025-12-09 | Qu Biologics Inc. | Innate targeting of adoptive cellular therapies |
| US10561686B2 (en) | 2018-01-12 | 2020-02-18 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| EP3544618A4 (en) * | 2018-01-11 | 2020-02-12 | Innovative Cellular Therapeutics Inc. | MODIFIED CELL EXPANSION AND USES THEREOF |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| GB201807862D0 (en) * | 2018-05-15 | 2018-06-27 | Ucl Business Plc | Chimeric antigen receptor |
| US12448426B2 (en) * | 2018-05-17 | 2025-10-21 | St. Jude Children's Research Hospital, Inc. | Chimeric antigen receptors with MYD88 and CD40 costimulatory domains |
| BR112020024292A2 (pt) | 2018-06-06 | 2021-03-02 | Massachusetts Institute Of Technology | rna circular para translação em células eucarióticas |
| EP3810755A4 (en) | 2018-06-19 | 2021-12-01 | Nantcell, Inc. | COMPOSITIONS AND METHODS OF TREATMENT FOR HIV |
| JP7447388B2 (ja) * | 2018-07-13 | 2024-03-12 | ナンジン レジェンド バイオテック カンパニー，リミテッド | 感染性疾患の治療のための共受容体システム |
| CN108948211B (zh) * | 2018-07-24 | 2021-08-20 | 北京美康基免生物科技有限公司 | 一种基于靶向gd2的嵌合抗原受体及其应用 |
| CA3107675A1 (en) * | 2018-07-30 | 2020-02-06 | University Of Southern California | Improving the efficacy and safety of adoptive cellular therapies |
| WO2020033430A1 (en) * | 2018-08-08 | 2020-02-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | High affinity monoclonal antibodies targeting glypican-2 and uses thereof |
| CN110845621A (zh) * | 2018-08-21 | 2020-02-28 | 上海恒润达生生物科技有限公司 | 一种靶向egfr和cd19双靶点的嵌合抗原受体方法 |
| CA3110926A1 (en) * | 2018-08-28 | 2020-03-05 | Pharos Vaccine Inc. | Improved lentiviral vector |
| US12240915B2 (en) | 2018-08-30 | 2025-03-04 | Innovative Cellular Therapeutics Holdings, Ltd. | Chimeric antigen receptor cells for treating solid tumor |
| CN109503716B (zh) * | 2018-10-08 | 2021-04-27 | 浙江生研生物科技有限公司 | 一种双特异性嵌合抗原受体分子及其在肿瘤治疗上的应用 |
| CN109266618B (zh) * | 2018-10-18 | 2021-04-23 | 赛元生物科技(杭州)有限公司 | 能够靶向肿瘤细胞的巨噬细胞及其制备方法 |
| WO2020080908A1 (ko) * | 2018-10-19 | 2020-04-23 | 주식회사 헬릭스미스 | 항-l1cam 항체 또는 그의 항원결합 단편, 및 이를 포함하는 키메라 항원 수용체 |
| AU2019372673A1 (en) | 2018-11-01 | 2021-05-27 | Gracell Biotechnologies (Shanghai) Co., Ltd. | Compositions and methods for T cell engineering |
| AU2019372331A1 (en) | 2018-11-01 | 2021-05-27 | Juno Therapeutics, Inc. | Methods for treatment using chimeric antigen receptors specific for B-cell maturation antigen |
| CN109400710A (zh) * | 2018-11-02 | 2019-03-01 | 山西大医院（山西医学科学院） | 一种靶向kif20a阳性胰腺癌双特异性抗体及其制备方法和应用 |
| BR112021009634A2 (pt) * | 2018-11-19 | 2021-08-10 | Board Of Regents, The University Of Texas System | gene suicida |
| US10918667B2 (en) | 2018-11-20 | 2021-02-16 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expressing therapeutic agent and uses thereof |
| AU2019397152A1 (en) * | 2018-12-14 | 2021-06-24 | 2Seventy Bio, Inc. | Dimerizing agent regulated immunoreceptor complexes |
| CN111748017A (zh) * | 2019-03-26 | 2020-10-09 | 上海瑞可新生物科技有限公司 | 一种抗原多肽及其表达载体、组合药物、试剂盒和应用 |
| US20220184129A1 (en) * | 2019-04-12 | 2022-06-16 | The Trustees Of The University Of Pennsylvania | Compositions and Methods Comprising a High Affinity Chimeric Antigen Receptor (CAR) with Cross-Reactivity to Clinically-Relevant EGFR Mutated Proteins |
| JP7595583B2 (ja) * | 2019-04-30 | 2024-12-06 | アタラ バイオセラピューティクス，インコーポレーテッド | 抗原特異的ｃｄ１９標的化ｃａｒ－ｔ細胞 |
| SG11202111130SA (en) | 2019-04-30 | 2021-11-29 | Senti Biosciences Inc | Chimeric receptors and methods of use thereof |
| CN114026118A (zh) * | 2019-05-07 | 2022-02-08 | 里兰斯坦福初级大学理事会 | 通过铰链结构域增强多肽和嵌合抗原受体 |
| WO2020227447A1 (en) * | 2019-05-07 | 2020-11-12 | The Board Of Trustees Of The Leland Stanford Junior University | Chimeric antigen receptors targeting glypican-2 |
| IL288284B2 (en) | 2019-05-22 | 2024-06-01 | Massachusetts Inst Technology | Circular rna compositions and methods |
| WO2020247837A1 (en) * | 2019-06-07 | 2020-12-10 | The Trustees Of The University Of Pennsylvania | Dual car expressing t cells individually linked to cd28 and 4-1bb |
| CN114174345B (zh) * | 2019-07-24 | 2024-11-26 | 瑞泽恩制药公司 | 具有mage-a4特异性的嵌合抗原受体和其用途 |
| CA3146298A1 (en) * | 2019-07-30 | 2021-02-04 | University Health Network | T cell receptors and methods of use thereof |
| US20210128617A1 (en) * | 2019-08-27 | 2021-05-06 | The Trustees Of The University Of Pennsylvania | SYNTHETIC CARS TO TREAT IL13R-alpha-2 POSITIVE HUMAN AND CANINE TUMORS |
| EP4054602A4 (en) * | 2019-11-08 | 2023-12-06 | Mayo Foundation for Medical Education and Research | EPHA3 TARGETED CAR-T CELLS FOR TREATING TUMORS |
| WO2021108670A1 (en) * | 2019-11-26 | 2021-06-03 | University Of Utah Research Foundation | Compositions and methods for upregulating hla class i on tumor cells |
| JP2023504568A (ja) | 2019-12-04 | 2023-02-03 | オルナ セラピューティクス インコーポレイテッド | 環状ｒｎａ組成物及び方法 |
| CN113106067B (zh) * | 2020-01-10 | 2024-06-21 | 南京大学 | 一种嵌合抗原受体-单核/巨噬细胞(car-m)的构建及其应用 |
| US12076343B2 (en) | 2020-02-19 | 2024-09-03 | Innovative Cellular Therapeutics Holdings, Ltd. | Engineered safety in cell therapy |
| CN113402612A (zh) | 2020-03-17 | 2021-09-17 | 西比曼生物科技（香港）有限公司 | 靶向cd19和cd20的联合嵌合抗原受体及其应用 |
| EP3892720A1 (en) * | 2020-04-06 | 2021-10-13 | Innovative Cellular Therapeutics Holdings, Ltd. | Presenting cell and use thereof in cell therapy |
| WO2021216731A1 (en) * | 2020-04-23 | 2021-10-28 | Innovative Cellular Therapeutics Holdings, Ltd. | Polyspecific binding molecules and their use in cell therapy |
| MX2022013898A (es) * | 2020-05-05 | 2023-02-09 | Regeneron Pharma | Car que comprende cd28 zeta y cd3 zeta. |
| US12043654B2 (en) | 2020-06-02 | 2024-07-23 | Innovative Cellular Therapeutics Holdings, Ltd. | Anti-GCC antibody and CAR thereof for treating digestive system cancer |
| IL298779A (en) * | 2020-06-08 | 2023-02-01 | Seattle Childrens Hospital Dba Seattle Childrens Res Inst | Anti-cd171 chimeric antigen receptors |
| WO2022036495A1 (en) | 2020-08-17 | 2022-02-24 | Utc Therapeutics Inc. | Lymphocytes-antigen presenting cells co-stimulators and uses thereof |
| US20240307539A1 (en) * | 2020-09-30 | 2024-09-19 | Institute Of Zoology, Chinese Academy Of Science | Egfr-targeting chimeric antigen receptor |
| AU2021397206A1 (en) * | 2020-12-08 | 2023-07-27 | Seattle Children's Hospital (dba Seattle Children's Research Institute) | Anti-egfr chimeric antigen receptors |
| EP4259285A4 (en) * | 2020-12-09 | 2024-12-11 | Affyimmune Therapeutics, Inc. | DUAL CHIMERIC ANTIGEN RECEPTOR TARGETING EPCAM AND ICAM-1 |
| CN114685683B (zh) * | 2020-12-31 | 2025-07-08 | 博生吉医药科技(苏州)有限公司 | 靶向gd2的car-t细胞及其制备和应用 |
| AU2022227686A1 (en) | 2021-02-25 | 2023-07-27 | Lyell Immunopharma, Inc. | Ror1 targeting chimeric antigen receptor |
| CN118056012B (zh) * | 2021-08-24 | 2025-05-30 | 赛斯尔擎生物技术（上海）有限公司 | 一种修饰细胞的方法 |
| US20250161447A1 (en) * | 2022-03-03 | 2025-05-22 | Board Of Regents, The University Of Texas System | Anti-cd19 and anti-cd79b chimeric antigen receptors and methods of use thereof |
| CN114573711A (zh) * | 2022-03-04 | 2022-06-03 | 陕西师范大学 | 一种TanCAR的构建及其应用 |
| CN114605560B (zh) * | 2022-03-30 | 2024-02-20 | 江苏蒙彼利生物科技有限公司 | 一种car-nk细胞及其制备方法与应用 |
| US12297285B2 (en) | 2022-06-24 | 2025-05-13 | Orna Therapeutics, Inc. | Circular RNA encoding chimeric antigen receptors targeting BCMA |
| WO2024026505A2 (en) * | 2022-07-29 | 2024-02-01 | Amit Patel | Disruption of telocyte activity |
| WO2024059733A2 (en) * | 2022-09-14 | 2024-03-21 | Fred Hutchinson Cancer Center | Chimeric antigen receptors binding nectin-4 |
| WO2024097911A1 (en) * | 2022-11-02 | 2024-05-10 | Fate Therapeutics, Inc. | Off-the-shelf therapeutic cells with multiplex genomic engineering for targeting gprc5d |
| WO2024131970A1 (zh) * | 2022-12-24 | 2024-06-27 | 深圳市菲鹏生物治疗股份有限公司 | 细胞组合物及其应用和药物 |
| KR20250131823A (ko) | 2023-03-31 | 2025-09-03 | 아벨제타 인크. | Cd20 및 bcma를 표적화하는 이중특이적 키메라 항원 수용체 |
| WO2025029484A1 (en) * | 2023-07-31 | 2025-02-06 | Bio4T2, Llc | Methods of blood cell-mediated in vivo car cell expansion and engraftment |
| CN117338914B (zh) * | 2023-10-27 | 2024-09-06 | 中山市珈钰生物医药有限公司 | 一种同种异体树突细胞肿瘤疫苗及其制备方法和应用 |
| WO2025113671A1 (zh) * | 2023-12-01 | 2025-06-05 | 上海邦耀生物科技有限公司 | Car、表达car的细胞及其用途 |
Family Cites Families (95)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0557459B1 (en) | 1990-11-13 | 1997-10-22 | Immunex Corporation | Bifunctional selectable fusion genes |
| US20020111474A1 (en) | 1990-12-14 | 2002-08-15 | Capon Daniel J. | Chimeric chains for receptor-associated signal transduction pathways |
| WO1994000143A1 (en) | 1992-06-01 | 1994-01-06 | New England Medical Center Hospitals, Inc. | Blocking intercellular interactions with cd43 chimeric molecules |
| US5827642A (en) | 1994-08-31 | 1998-10-27 | Fred Hutchinson Cancer Research Center | Rapid expansion method ("REM") for in vitro propagation of T lymphocytes |
| US5783186A (en) | 1995-12-05 | 1998-07-21 | Amgen Inc. | Antibody-induced apoptosis |
| US6660257B1 (en) | 1996-10-25 | 2003-12-09 | Pharmacia Corporation | Circular permuteins of flt3 ligand |
| AU2472400A (en) | 1998-10-20 | 2000-05-08 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
| GB0015119D0 (en) | 2000-06-20 | 2000-08-09 | Angeletti P Ist Richerche Bio | Methods and means for regulation of gene expression |
| EP1297168A2 (en) | 2000-07-03 | 2003-04-02 | Gala Design, Inc. | Expression vectors |
| EP1334188B1 (en) | 2000-11-07 | 2006-08-30 | City of Hope | Cd19-specific redirected immune cells |
| BR0207854A (pt) | 2001-03-07 | 2004-08-24 | Merck Patent Gmbh | Tecnologia de expressão para proteìnas contendo uma porção de anticorpo de isotipo hìbrido |
| US7070995B2 (en) * | 2001-04-11 | 2006-07-04 | City Of Hope | CE7-specific redirected immune cells |
| US20090257994A1 (en) | 2001-04-30 | 2009-10-15 | City Of Hope | Chimeric immunoreceptor useful in treating human cancers |
| WO2002097099A1 (en) | 2001-05-29 | 2002-12-05 | Valentis, Inc. | Regulated expression of ghrh |
| WO2003025228A1 (en) | 2001-09-18 | 2003-03-27 | Proteologics, Inc. | Methods and compositions for treating hcap associated diseases |
| US20030148982A1 (en) | 2001-11-13 | 2003-08-07 | Brenner Malcolm K. | Bi-spcific chimeric T cells |
| MXPA04009809A (es) | 2002-04-11 | 2004-12-13 | Amgen Inc | Moleculas de tirosina cinasa del receptor her-2 y uso de las mismas. |
| US20040115814A1 (en) | 2002-09-30 | 2004-06-17 | Protein Design Labs, Inc. | Efficient generation of stable expression cell lines through the use of scorable homeostatic reporter genes |
| US20040158329A1 (en) | 2003-02-10 | 2004-08-12 | Waldemar Link (Gmbh & Co.) | Hip joint prosthesis with shaft inserted into femur |
| WO2004073656A2 (en) | 2003-02-20 | 2004-09-02 | Seattle Genetics, Inc. | Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders |
| US20050129671A1 (en) | 2003-03-11 | 2005-06-16 | City Of Hope | Mammalian antigen-presenting T cells and bi-specific T cells |
| US20060160090A1 (en) | 2003-04-11 | 2006-07-20 | Macina Robert A | Composition splice variants and methods relating to cancer specific genes and proteins |
| WO2005017102A2 (en) | 2003-05-30 | 2005-02-24 | Diadexus, Inc. | Compositions, splice variants and methods relating to ovarian specific nucleic acids and proteins |
| JP4772674B2 (ja) | 2003-07-21 | 2011-09-14 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー | ヒト上皮成長因子２／ｎｅｕ抗原をコードする合成遺伝子およびその用途 |
| WO2005040212A2 (en) | 2003-10-24 | 2005-05-06 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Orthogonal gene switches |
| US20130266551A1 (en) | 2003-11-05 | 2013-10-10 | St. Jude Children's Research Hospital, Inc. | Chimeric receptors with 4-1bb stimulatory signaling domain |
| WO2005062881A2 (en) | 2003-12-24 | 2005-07-14 | Transgenrx, Inc. | Gene therapy using transposon-based vectors |
| US20090098142A1 (en) | 2004-06-09 | 2009-04-16 | Kasaian Marion T | Methods and compositions for treating and monitoring treatment of IL-13-associated disorders |
| US7910101B2 (en) | 2004-10-25 | 2011-03-22 | Centocor, Inc. | Melanocortin receptor binding mimetibodies, compositions, methods and uses |
| KR20080090441A (ko) * | 2005-12-21 | 2008-10-08 | 메디뮨 엘엘씨 | Ｅｐｈａ２ ｂｉｔｅ 분자 및 이의 용도 |
| BRPI0711207A2 (pt) | 2006-05-22 | 2011-03-22 | Hiprocell Llc | vetor alvo para intregação em sìtios-especificos, método de sìtio-especìfico que integra um polinucleotìdeo codificando uma proteina de interesse em um genoma de uma célula eucariótia, célula eucariótica isolada , kit para uso no sìtio-especìfico que integra um polinucleotideo dentro de um genoma de uma celula in vitro e kit para uso em produzir uma proteìna em célula |
| WO2008012237A1 (en) | 2006-07-24 | 2008-01-31 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa | Multi-antigen construct and uses thereof |
| US7709253B2 (en) | 2006-08-04 | 2010-05-04 | The Board Of Trustees Of The Leland Stanford Junior University | Ligand-regulable transactivation systems, methods of use thereof, methods of detecting estrogen receptor ligands, and methods of differentiating estrogen receptor ligand agonists and antagonists |
| CA2693155A1 (en) | 2007-07-25 | 2009-01-29 | Fraunhofer Gesellschaft Zur Forderung Der Angewandten Forschung E.V. | Self coupling recombinant antibody fusion proteins |
| WO2009091826A2 (en) | 2008-01-14 | 2009-07-23 | The Board Of Regents Of The University Of Texas System | Compositions and methods related to a human cd19-specific chimeric antigen receptor (h-car) |
| DK2279253T3 (en) | 2008-04-09 | 2017-02-13 | Maxcyte Inc | Construction and application of therapeutic compositions of freshly isolated cells |
| PL3006459T3 (pl) | 2008-08-26 | 2022-01-17 | City Of Hope | Sposób i kompozycje dla wzmocnionego działania efektorowego komórek t przeciw guzowi nowotworowemu |
| US8829173B2 (en) | 2008-09-26 | 2014-09-09 | Tocagen Inc. | Recombinant vectors |
| WO2010036986A2 (en) | 2008-09-26 | 2010-04-01 | Tocagen Inc. | Recombinant vectors |
| US8329882B2 (en) | 2009-02-18 | 2012-12-11 | California Institute Of Technology | Genetic control of mammalian cells with synthetic RNA regulatory systems |
| WO2010141543A1 (en) | 2009-06-02 | 2010-12-09 | Targeted Molecular Diagnostics, Llc | Methods for the detection and quantitation of the p95 component of her2/neu (erbb2) |
| US8075895B2 (en) | 2009-09-22 | 2011-12-13 | Janssen Pharmaceutica N.V. | Identification of antigenic peptides from multiple myeloma cells |
| ES2911246T3 (es) | 2009-11-03 | 2022-05-18 | Hope City | Receptor del factor de crecimiento epidérmico truncado (EGFRT) para selección de células T transducidas |
| JP5285678B2 (ja) | 2010-06-18 | 2013-09-11 | 株式会社エヌ・ティ・ティ・ドコモ | 移動通信方法及びコアネットワーク装置 |
| US9212229B2 (en) | 2010-09-08 | 2015-12-15 | Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus | Chimeric antigen receptors with an optimized hinge region |
| PH12013501201A1 (en) | 2010-12-09 | 2013-07-29 | Univ Pennsylvania | Use of chimeric antigen receptor-modified t cells to treat cancer |
| AU2012207356A1 (en) | 2011-01-18 | 2013-08-01 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating cancer |
| KR101976882B1 (ko) | 2011-03-23 | 2019-05-09 | 프레드 헛친슨 켄서 리서치 센터 | 세포 면역요법용 방법 및 조성물 |
| CN103502439B (zh) | 2011-04-13 | 2016-10-12 | 因缪尼卡姆股份公司 | 用于抗原特异性t细胞增殖的方法 |
| DK3489366T3 (da) | 2011-06-01 | 2020-02-24 | Prec Biosciences Inc | Fremgangsmåder og produkter til produktion af manipulerede mammale cellelinier med forstærkede transgener |
| ES2667864T3 (es) | 2011-06-22 | 2018-05-14 | F. Hoffmann-La Roche Ag | Eliminación de células diana mediante linfocitos T citotóxicos específicos de virus en circulación usando complejos que comprenden MHC de clase I |
| DE102011118018B4 (de) | 2011-10-25 | 2017-10-26 | Plasmidfactory Gmbh & Co. Kg | Minicircles mit Transpositionskassetten und ihre Verwendung zur Transformation von Zellen |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| JP6850528B2 (ja) * | 2012-02-13 | 2021-03-31 | シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート | 二重特異性キメラ抗原受容体およびその治療的使用 |
| ITRM20120058A1 (it) | 2012-02-20 | 2013-08-21 | Pisanelli Giovanni Codacci | Famiglia di molecole a base di zuccheri ad uso terapeutico e relativo procedimento di produzione |
| EP2817330B1 (en) | 2012-02-22 | 2020-07-08 | The Trustees of the University of Pennsylvania | Use of icos-based cars to enhance antitumor activity and car persistence |
| WO2013154760A1 (en) | 2012-04-11 | 2013-10-17 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting b-cell maturation antigen |
| US20130280220A1 (en) | 2012-04-20 | 2013-10-24 | Nabil Ahmed | Chimeric antigen receptor for bispecific activation and targeting of t lymphocytes |
| US9540657B2 (en) | 2012-05-25 | 2017-01-10 | California Institute Of Technology | Expression of secreted and cell-surface polypeptides |
| KR20150027756A (ko) | 2012-05-30 | 2015-03-12 | 베일러 칼리지 오브 메디신 | Dna 수복, 변경 및 대체를 위한 도구로서의 초나선 미니벡터 |
| EP2669378A1 (en) | 2012-05-31 | 2013-12-04 | Helmut Hanenberg | Cytochrome P450 suicide gene system |
| WO2013180287A1 (ja) | 2012-06-01 | 2013-12-05 | 日本電気株式会社 | スイッチングシステム、ラインカード、スイッチカード、ｆｄｂ学習方法、ｆｄｂ学習調停方法及びプログラム |
| PL2884999T3 (pl) * | 2012-08-20 | 2021-07-05 | Fred Hutchinson Cancer Research Center | Sposób i kompozycje do immunoterapii komórkowej |
| WO2014039044A1 (en) | 2012-09-06 | 2014-03-13 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing t memory stem cell populations |
| RU2729401C2 (ru) | 2012-10-02 | 2020-08-06 | Мемориал Слоан-Кеттеринг Кэнсер Сентер | Композиции и способы для иммунотерапии |
| WO2014055657A1 (en) | 2012-10-05 | 2014-04-10 | The Trustees Of The University Of Pennsylvania | Use of a trans-signaling approach in chimeric antigen receptors |
| WO2014099671A1 (en) | 2012-12-20 | 2014-06-26 | Bluebird Bio, Inc. | Chimeric antigen receptors and immune cells targeting b cell malignancies |
| EP2964753B1 (en) | 2013-03-07 | 2018-04-25 | Baylor College of Medicine | Targeting cd138 in cancer |
| EP2777711A1 (en) | 2013-03-11 | 2014-09-17 | Icon Genetics GmbH | Her2/Neu cancer vaccine |
| UY35468A (es) | 2013-03-16 | 2014-10-31 | Novartis Ag | Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19 |
| WO2014190273A1 (en) | 2013-05-24 | 2014-11-27 | Board Of Regents, The University Of Texas System | Chimeric antigen receptor-targeting monoclonal antibodies |
| AU2014342020C1 (en) * | 2013-10-31 | 2019-09-05 | Fred Hutchinson Cancer Research Center | Modified hematopoietic stem/progenitor and non-T effector cells, and uses thereof |
| WO2015075468A1 (en) * | 2013-11-21 | 2015-05-28 | Ucl Business Plc | Cell |
| AU2014368383B2 (en) | 2013-12-20 | 2020-01-16 | Cellectis | Method of engineering multi-input signal sensitive T cell for immunotherapy |
| EP3626748A1 (en) * | 2014-01-13 | 2020-03-25 | Stephen J. Forman | Chimeric antigen receptors (cars) having mutations in the fc spacer region and methods for their use |
| KR102375998B1 (ko) | 2014-02-14 | 2022-03-21 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 키메라 항원 수용체 및 제조방법 |
| WO2015142675A2 (en) | 2014-03-15 | 2015-09-24 | Novartis Ag | Treatment of cancer using chimeric antigen receptor |
| SG11201608393TA (en) * | 2014-04-10 | 2016-11-29 | Seattle Children S Hospital Dba Seattle Children S Res Inst | Transgene genetic tags and methods of use |
| WO2015172339A1 (zh) | 2014-05-14 | 2015-11-19 | 科济生物医药（上海）有限公司 | 编码嵌合抗原受体蛋白的核酸及表达嵌合抗原受体蛋白的t淋巴细胞 |
| AU2015270912B9 (en) | 2014-06-02 | 2021-01-21 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Chimeric antigen receptors targeting CD-19 |
| TWI805109B (zh) | 2014-08-28 | 2023-06-11 | 美商奇諾治療有限公司 | 對cd19具專一性之抗體及嵌合抗原受體 |
| CN107106611B (zh) | 2014-10-27 | 2021-11-23 | 弗雷德哈钦森癌症研究中心 | 用于提高过继细胞免疫疗法效力的组合物和方法 |
| GB201503742D0 (en) | 2015-03-05 | 2015-04-22 | Ucl Business Plc | Chimeric antigen receptor |
| KR20180029201A (ko) | 2015-05-18 | 2018-03-20 | 티씨알2 테라퓨틱스 인크. | 융합 단백질을 이용하는 tcr 리프로그래밍을 위한 조성물 및 방법 |
| KR20240013282A (ko) | 2015-06-10 | 2024-01-30 | 이뮤너티바이오, 인크. | 암을 치료하기 위한 변형된 nk-92 세포 |
| EP4286511A3 (en) | 2015-06-12 | 2024-03-06 | Lentigen Technology, Inc. | Method to treat cancer with engineered t-cells |
| US11458167B2 (en) | 2015-08-07 | 2022-10-04 | Seattle Children's Hospital | Bispecific CAR T-cells for solid tumor targeting |
| AU2017213661B2 (en) | 2016-02-05 | 2022-06-02 | City Of Hope | Administration of engineered T cells for treatment of cancers in the central nervous system |
| WO2017172952A1 (en) | 2016-04-01 | 2017-10-05 | Promab Biotechnologies, Inc. | Flag tagged cd19-car-t cells |
| PL3518972T3 (pl) | 2016-09-28 | 2025-04-07 | Kite Pharma, Inc. | Cząsteczki wiążące antygen i sposoby ich zastosowania |
| JP6887492B6 (ja) | 2016-10-04 | 2021-07-14 | プレシジョン バイオサイエンシズ，インク． | 遺伝子改変細胞で使用するための共刺激ドメイン |
| CN110291200B (zh) | 2016-12-12 | 2024-05-14 | 西雅图儿童医院（Dba西雅图儿童研究所） | 对哺乳动物细胞中转基因表达的药剂配体诱导具有增大的灵敏度的嵌合转录因子变异体 |
| JOP20180042A1 (ar) | 2017-04-24 | 2019-01-30 | Kite Pharma Inc | نطاقات ربط مولد ضد متوافقة مع البشر وطرق الاستخدام |
| US10869888B2 (en) | 2018-04-17 | 2020-12-22 | Innovative Cellular Therapeutics CO., LTD. | Modified cell expansion and uses thereof |
| US11104732B2 (en) | 2019-04-24 | 2021-08-31 | Innovative Cellular Therapeutics Holdings, Ltd. | Reducing immune inhibition induced by SIGLEC-15 |
-
2016
- 2016-08-03 US US15/750,708 patent/US11458167B2/en active Active
- 2016-08-03 CN CN201680058143.5A patent/CN108174604B/zh active Active
- 2016-08-03 CA CA2994829A patent/CA2994829A1/en active Pending
- 2016-08-03 JP JP2018506286A patent/JP7162530B2/ja active Active
- 2016-08-03 HK HK18115149.8A patent/HK1256087A1/zh unknown
- 2016-08-03 AU AU2016306209A patent/AU2016306209B2/en active Active
- 2016-08-03 WO PCT/US2016/045360 patent/WO2017027291A1/en not_active Ceased
- 2016-08-03 EP EP16835650.9A patent/EP3331920A4/en active Pending
- 2016-08-03 MX MX2018001568A patent/MX2018001568A/es unknown
-
2020
- 2020-11-03 US US17/088,005 patent/US11123369B2/en active Active
-
2022
- 2022-04-20 JP JP2022069615A patent/JP7566817B2/ja active Active
- 2022-09-12 US US17/931,258 patent/US20230130938A1/en active Pending
-
2023
- 2023-10-05 AU AU2023241321A patent/AU2023241321A1/en active Pending
-
2024
- 2024-10-02 JP JP2024172910A patent/JP2025000906A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018522567A5 (enExample) | ||
| US11123369B2 (en) | Bispecific CAR T-cells for solid tumor targeting | |
| JP7527049B2 (ja) | Ｃａｒ発現ベクター及びｃａｒ発現ｔ細胞 | |
| JP7267321B2 (ja) | 改善された特異性を有する改変型ｔリンパ球 | |
| He et al. | Targeting cancers through TCR-peptide/MHC interactions | |
| JP7221213B2 (ja) | 多官能性タンパク質 | |
| ES2732067T3 (es) | Receptor de antígeno quimérico (CAR) que contiene un dominio de unión a CD19 | |
| ES2681948T3 (es) | Células de acoplamiento para inmunoterapia | |
| ES2786263T3 (es) | Mejora de la actividad de los CAR de linfocitos T mediante la introducción conjunta de un anticuerpo biespecífico | |
| ES2833162T5 (es) | Receptor de antígeno quimérico y su uso | |
| Leisegang et al. | T-Cell Receptor Gene–Modified T Cells with Shared Renal Cell Carcinoma Specificity for Adoptive T-Cell Therapy | |
| US11890302B2 (en) | Gamma delta CAR-T cells comprising Fc gamma intracellular signaling domains | |
| WO2022033537A1 (zh) | 工程化免疫细胞及其用途 | |
| JP2023515655A (ja) | 改変免疫細胞とその使用 | |
| Essand et al. | Genetically engineered T cells for the treatment of cancer | |
| JP2015509717A (ja) | 抗腫瘍活性およびｃａｒ存続性を強化するためのｉｃｏｓベースのｃａｒの使用 | |
| JP2024054286A (ja) | 操作された細胞、ｔ細胞免疫調節抗体、およびそれらの使用方法 | |
| US20250002855A1 (en) | Methods for expanding t cells for the treatment of cancer and related malignancies | |
| Golubovskaya | CAR-T cells targeting immune checkpoint pathway players | |
| WO2022223049A1 (zh) | 工程化免疫细胞及其用途 | |
| WO2023051361A1 (zh) | 工程化免疫细胞及其用途 | |
| Yu et al. | CAR NK cell therapy for solid tumors: Potential and challenges | |
| WO2023035947A1 (zh) | 工程化免疫细胞及其用途 | |
| Kebriaei et al. | CARs: driving T-cell specificity to enhance anti-tumor immunity | |
| US20250332195A1 (en) | Chimeric antigen receptor, cell expressing said receptor, pharmaceutical composition including said cell, method for producing said cell, and polynucleotide or vector including nucleotide sequence encoding said chimeric antigen receptor |